Which may result in changes in hepatitis B liver cancer?

It is reported that recently, 90 per cent of liver cancer (the topic of the Advisory interview) in patients with hepatitis B have a history, suffered from hepatitis B than other people suffering from liver cancer risk of up to 10.7 times that of people suffering from hepatitis B virus to carry the risk of liver cancer The health of the population is 6.37 times! Why is hepatitis B virus is prone to lead to liver cancer? In a few days ago with "viral hepatitis and hepatocellular carcinoma in Asia" as the theme of the 17th annual meeting of liver disease in the Asia Pacific region, China, South Korea, Japan, Australia and the Asia-Pacific region, such as liver disease prevention and control large number of experts and scholars warned that if the You are infected with hepatitis B virus, or your doctor is a hepatitis B patients have to bear in mind the following points away from the risk factors in order to stay away from hepatocarcinoma invasion: 1. Drink. Long-term drinking of hepatitis B surface antigen-positive can promote the occurrence of liver cirrhosis or liver cancer; 2. Rotten food oil. Well-worn animal and plant oil is toxic and may cause cancer; 3. Moldy food to eat. When they find food, oil, dairy products have mold contamination, the ban on consumption; 4. Let matters drift. Hepatitis B patients and their families to the hospital on a regular basis should be checks on a regular basis to review serum aminotransferase, six months to a year "half-and-half," once a fetus fetal globulin, an annual inspection super-B. Otherwise, let matters drift, persistent infection of hepatitis B virus replication, inflammation to fibrosis of the lesion, will inevitably lead to cirrhosis or liver cancer incidence. 5. Disorder medication. In the face of an increased range of drugs, experts say patients should be careful to choose, the 2007 edition of "Guide to Prevention of Hepatitis B" is the international treatment of chronic hepatitis B treatment in the field of the latest regulatory guidance documents, with a high reference value. Liver disease experts have pointed out that a clear understanding of the needs, "not only anti-virus capability, but also easy to take and the low rate of drug resistance and side effects of small and cheap prices, such an ideal drug, there is no market."